Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novo Nordisk and Glooko Partner to Improve Diabetes Management

XTALKS VITALS NEWS

Blood Glucose

The pharmaceutical company will apply Glooko’s FDA-cleared, HIPPA-compliant platform to develop an app designed to help diabetic patients improve their blood glucose control.

Share this!

January 10, 2017 | by Sarah Hand, M.Sc.

Danish diabetes drugmaker, Novo Nordisk, has partnered with mHealth company, Glooko, to develop patient-centric apps for better diabetes management. The pharmaceutical company will apply Glooko’s FDA-cleared, HIPPA-compliant platform to develop an app designed to help diabetic patients improve their blood glucose control.

Novo Nordisk is the world’s leading supplier of diabetes medications. The partnership will provide California-based Glooko with access to Novo Nordisk’s customer information, along with its diabetes-based educational resources.

“We will add that [content] to our mobile platform,” Glooko CEO Rick Altinger told MedCity News. “The vision is to leverage data to drive better and faster decisions to help patients and their caregivers get to better outcomes.”

Glooko’s diabetes management platform has allowed the company to collect patient data on about one million diabetic patients globally. In addition, over 4,800 health systems have adopted the technology for disease management and remote patient monitoring.



According to Altinger, Glooko not only helps patients track all of the variables that affect their diabetes management, but it also offers companies a way to add diabetes information into electronic health records (EHR). “Diabetes is a data-driven disease, said Altinger. “Health systems can pull in data from Glooko, into workflows and integrate with EHRs if they want.”

Aside from this most recent deal with Novo Nordisk, Glooko has already established deals with diabetes medical device makers, including Roche. As the agreement with Novo Nordisk is nonexclusive, the company’s partnership with IBM Watson Health will likely also come into play.

“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” said Christian Kanstrup, Novo Nordisk’s senior vice president for strategy, access and marketing. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

While it’s unclear exactly what products will come out of the partnership, Glooko has said that personalized support for diabetic patients and their caregivers is the major goal. The first digital health offering could be made available before the end of this year.


Keywords: Diabetes, mHealth, Disease Management


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.